Microbot Medical (MBOT) delivered earnings and revenue surprises of +37.50% and -76.67%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

MBOT moves to full U.S. launch of its LIBERTY robotic system after strong hospital adoption, boosting momentum for faster market uptake and sales growth.

BRAINTREE, Mass., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (MBOT) (“Microbot” or the “Company”), today announced the entry into definitive agreements for the exercise of certain ...

Microbot Medical Inc. has appointed Ms. Michal Ahuvia as the new Director of Operations to enhance production and efficiency ahead of the commercial launch of their LIBERTY® Endovascular Robotic ...

Commercial adoption of the LIBERTY System by sites that participated in the clinical trial serves as a strong validation of the value it brings ...

Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY ® Endovascular Robotic System, announced that it will highlight recent commercial achievements leading to the ...

Microbot Medical Inc. (MBOT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ...

HINGHAM, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 701,756 shares of the Company ...

Microbot Medical Inc. Annual stock financials by MarketWatch. View the latest MBOT financial statements, income statements and financial ratios.

BRAINTREE, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under ...